Wednesday, July 8, 2026

pharma · Renal Impairment · Urinary Tract Infection · SPRO

Spero Therapeutics

Spero Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SPRO. Primary therapeutic focus areas include Renal Impairment, Urinary Tract Infection, complicated urinary tra

675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
Status
Public
HQ
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
Founded
2013
Employees
45
Programs
21
Drugs
9
Patents
16
Clinical program

SPR206

Phase 1 · small molecule · Healthy Volunteers

SPR206 for Healthy Volunteers is a Phase 1 program (small_molecule) at Spero Therapeutics with 1 ClinicalTrials.gov record(s).

← All Spero Therapeutics projects Phase 1 small molecule completed

Internal code SPR206-102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Spero Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers
Status
completed
Trials
1

Clinical trials